Medpace
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Medpace and other ETFs, options, and stocks.About MEDP
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
CEOAugust James Troendle
CEOAugust James Troendle
Employees5,900
Employees5,900
HeadquartersCincinnati, Ohio
HeadquartersCincinnati, Ohio
Founded1992
Founded1992
Employees5,900
Employees5,900
MEDP Key Statistics
Market cap16.63B
Market cap16.63B
Price-Earnings ratio41.36
Price-Earnings ratio41.36
Dividend yield—
Dividend yield—
Average volume252.03K
Average volume252.03K
High today$600.37
High today$600.37
Low today$583.79
Low today$583.79
Open price$588.09
Open price$588.09
Volume183.85K
Volume183.85K
52 Week high$625.00
52 Week high$625.00
52 Week low$250.05
52 Week low$250.05
Stock Snapshot
The current Medpace(MEDP) stock price is $590.09, with a market capitalization of 16.63B. The stock trades at a price-to-earnings (P/E) ratio of 41.36.
During the trading session on 2025-11-14, Medpace(MEDP) shares reached a daily high of $600.37 and a low of $583.79. At a current price of $590.09, the stock is +1.1% higher than the low and still -1.7% under the high.
Trading activity shows a volume of 183.85K, compared to an average daily volume of 252.03K.
The stock's 52-week range extends from a low of $250.05 to a high of $625.00.
The stock's 52-week range extends from a low of $250.05 to a high of $625.00.
Analyst ratings
62%
of 13 ratingsBuy
7.7%
Hold
61.5%
Sell
30.8%
People also own
Based on the portfolios of people who own MEDP. This list is generated using Robinhood data, and it’s not a recommendation.